Guggenheim Reiterates Buy Rating for Monte Rosa Therapeutics
Guggenheim maintains a bullish stance on Monte Rosa Therapeutics with a $35 price target, a 44.63% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Monte Rosa Therapeutics, setting a price target of $35.
- Guggenheim's $35 price target implies 44.63% upside from Monte Rosa Therapeutics, Inc.'s ($GLUE) current $24.20 share price.
- Shares of NasdaqGS:GLUE traded near $23.90 on Tuesday, with a market cap of about $1.88 billion.
- Monte Rosa Therapeutics has seen varied institutional activity with notable increases from Price T Rowe and Versant Ventures.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating for Monte Rosa Therapeutics, Inc. (NasdaqGS:GLUE) on June 30, 2026. Analyst Michael Schmidt set a price target of $35, reflecting continued confidence in the company's prospects. Shares of Monte Rosa traded near $23.90 on the same day.
Other Institutional Activity in Monte Rosa Therapeutics
Several institutional investors have shown interest in Monte Rosa Therapeutics. Price T Rowe Associates increased its holdings by 1,601,284 shares, ending with 6,720,188 shares valued at approximately $110.5 million, a 31.3% increase. Versant Venture Management also grew its stake by 1,978,873 shares, holding 6,361,560 shares worth around $104.6 million, marking a 45.2% rise. BlackRock, Inc. added 1,456,523 shares to its portfolio, now holding 5,637,684 shares valued at about $92.7 million, a 34.8% increase.
Monte Rosa Therapeutics, Inc. Stock Up 80.9%
On Tuesday, shares of Monte Rosa Therapeutics traded near $23.90. The company has a market cap of roughly $1.88 billion. While it is not currently profitable, it has a forward P/E ratio of -12.29. The stock has a 52-week low of $4.12 and a high of $25.77, with a 50-day moving average of $18.98 and a 200-day moving average of $16.24. The company maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44, alongside a debt-to-equity ratio of 7.49.
$GLUE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Monte Rosa Therapeutics reported revenue of $42.95 million, though it experienced a revenue decline of 95%. The company's net margin stands at 0%, with a return on equity of -32.62%. The next earnings release is expected on August 6, 2026.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
Recent insider activity includes Chief Medical Officer Filip Janku buying 30,000 shares at an average price of $7.56 on June 24, 2026. On the same day, he sold 30,000 shares at an average price of $21.42 under a Rule 10b5-1 plan. Chief Operating Officer Jennifer Champoux purchased 2,175 shares at $3.98 on June 23, 2026.
Analysts Set New Price Targets
On June 30, 2026, Guggenheim maintained its buy rating with a $35 price target. JP Morgan also maintained a buy rating with a $31 target on May 11, 2026. The consensus among six analysts is a buy rating, with a mean target price of $32.33.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, headquartered in Boston, Massachusetts, is a biotechnology company focused on developing small molecule precision medicines. It specializes in creating molecular glue degraders to treat various conditions, including MYC-driven tumors, autoimmune and inflammatory diseases, and multiple cancers. The company collaborates with F. Hoffmann-La Roche and Novartis and is led by CEO Dr. Markus Warmuth.
Bottom Line
Guggenheim's reiterated buy rating with a $35 target underscores confidence in Monte Rosa Therapeutics' potential. Investors track such analyst updates as they can influence stock performance. As a reminder, these analyses reflect backward-looking data and may not represent current market conditions.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.